Subclinical left ventricular dysfunction in men under androgen deprivation therapy for prostate cancer, revealed by speckle-tracking-derived parameters, repolarization, and myocardial injury markers

Andrei C. D. Gheorghe MD, PhD1,2 | Ana Ciobanu MD, PhD1,2 | Andreea S. Hodorogea MD, PhD1,2 | George D. Radavoi MD, PhD1,3 | Viorel Jinga MD, PhD1,3 | Alexandru S. C. Rascu MD, PhD1,3 | Ioan T. Nanea MD, PhD1,2 | Gabriela S. Gheorghe MD, PhD1,2

1Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
2Department of Internal Medicine and Cardiology, Theodor Burghel Clinical Hospital, Bucharest, Romania
3Department of Urology, Theodor Burghel Clinical Hospital, Bucharest, Romania

Correspondence
Ana Ciobanu, Department of Internal Medicine and Cardiology, Theodor Burghel Clinical Hospital, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 20 Panduri street, district 5, 050659, Bucharest, Romania.
Email: ana.ciobanu@outlook.com, ana.ciobanu@umfcd.ro

Funding information
None.

Abstract
Objective: To analyze global left ventricular longitudinal strain (GLS), mechanical dispersion (MD), electrocardiographic repolarization, and myocardial injury markers changes during androgen deprivation therapy (ADT) and subsequent hypogonadism in men with advanced prostate cancer.

Methods: We included 31 patients 69.7 ± 7.3 years old, in sinus rhythm, with stable cardiac conditions and evaluated them by echocardiography, electrocardiography, and blood sampling for high sensitivity cardiac troponin I (hs-cTnI), and N-terminal pro-brain natriuretic peptide (NTproBNP), at ADT initiation (M0) and after 6 months of treatment (M1). Peak longitudinal strain by speckle-tracking echocardiography was assessed in 17 left ventricular segments and averaged to GLS. Standard deviation of time intervals from the start of Q/R on electrocardiogram to peak longitudinal strain in the 17 segments (MDSD), and the difference between the longest and shortest time-to-peak strain intervals (MDdelta) were calculated as indices of MD. Fridericia corrected electrocardiographic repolarization parameters were analyzed as follows: QT interval (QTc), mean and maximum values of Tpeak-Tend interval (Tpe), and Tpe/QT ratio, Tpe dispersion (Tped).

Results: Significant impairments of the following parameters were registered between M0 and M1: GLS (%) (−16.93 ± 3.89; −14.43 ± 3.57, P < .001), MDSD (ms) (77.4 ± 21.4; 89 ± 27, P = .004), MDdelta (ms) (225.3 ± 78.3; 259.9 ± 108.4, P = .02), QTc (ms) (458.8 ± 43.4; 485.6 ± 45.1, P = .01), maxTpe/QT (0.246 ± 0.04; 0.268 ± 0.04, P = .01), maxTpe (ms) (105.4 ± 23.2; 119.5 ± 26.4 P = .01), meanTpe (ms) (83.3 ± 16.8; 90.7 ± 19.3, P = .02), and hs-cTnI (ng/mL) (4.6 ± 5.4; 5.4 ± 6.4, P = .01). Mean serum testosterone level at M1 was 0.1 ± 0.13 ng/mL. The patients' clinical cardiological status remained stable during follow-up.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. Echocardiography published by Wiley Periodicals LLC.
Conclusions: ADT and subsequent hypogonadism induce subclinical alterations in GLS, MD, electrocardiographic repolarization parameters, and hs-cTnl during the first 6 months of treatment.

KEYWORDS
brain natriuretic peptide, cardiac toxicity, left ventricular function, myocardial strain, transthoracic echocardiography

1 | INTRODUCTION

Cardio-oncology investigates the cardiotoxicity of chemotherapy, radiotherapy, and other oncological therapies such as biological therapy, monoclonal antibody therapy, and hormone therapy. Some studies but not all suggest that androgen deprivation therapy (ADT) indicated in advanced prostate cancer, and its subsequent hypogonadism can induce cardiac electrical instability and cardiotoxicity. It is difficult to separate the deleterious cardiac effects of hypogonadism itself from those of ADT, both of them being able to damage the cardiac repolarization parameters and to increase the risk of severe ventricular arrhythmias. However, clinical studies have indicated that, compared with orchietomy, the use of ADT is associated with a higher risk of coronary heart disease, sudden cardiac death, and myocardial infarction. There are no consensus guidelines for cardiotoxicity assessment during ADT, as there are for chemotherapy, where longitudinal global strain (GLS) reduction of more than 15% from baseline, left ventricular ejection fraction (LVEF) decrease of more than 10% below the lower limit of normal and prolongation of corrected QT interval (QTc) on ECG suggest cardiotoxicity. GLS impairment is more sensitive than LVEF in predicting cardiac side effects of chemotherapy. Simultaneous reduction in GLS and elevation of high sensitivity cardiac troponin improves cardiotoxicity risk assessment.

Mechanical dispersion reflects cardiac electrical abnormalities including both activation time and refractoriness. A prolonged mechanical dispersion assessed by the standard deviation of time-to-peak myocardial longitudinal strain intervals in the 17-segment left ventricular model (MD_{17S}), and the difference between the longest and shortest time-to-peak strain intervals (MD_{com}) showed to be a predictive factor for ventricular arrhythmias and sudden cardiac death after myocardial infarction, in hypertrophic cardiomyopathy and long QT syndrome, and could improve the cardiac evaluation of patients under oncological treatments.

We aimed to evaluate the cardiac effects of ADT and subsequent hypogonadism in patients with advanced prostate cancer by analyzing speckle-tracking-derived parameters of left ventricular function in relation to repolarization and myocardial injury markers changes.

2 | METHODS

We conducted a longitudinal observational analytical study and included consecutive patients with the diagnosis of advanced prostate cancer treated with ADT, in accordance with urological and oncological recommendations. The study protocol was approved by the local ethics committee and was conducted according to the ethical principles stated in the Declaration of Helsinki. All patients were informed about the aim of the study and signed written informed consent before inclusion.

The patients were screened 5-7 days before beginning ADT and included if they were in sinus rhythm, had optimal echocardiographic windows and no cardiac diseases or at most chronic coronary syndrome, treated arterial hypertension, myocardial infarction more than 6 months before screening, NYHA class I-II heart failure, LVEF ≥45%, estimated glomerular filtration rate >30 mL/min/1.73 m², diabetes mellitus with glycosylated hemoglobin ≤7.5%, normal serum potassium, and magnesium and calcium levels.

The exclusion criteria were unstable angina, recent myocardial infarction, NYHA class III-IV heart failure, LVEF <45%, sustained ventricular tachycardia, persistent or permanent atrial fibrillation, complete bundle branch block, diabetes mellitus with glycosylated hemoglobin >7.5%, grade 4-5 chronic kidney disease, electrolyte disturbances, chronic use of drugs known to prolong QTc, life expectancy less than 6 months, and poor echocardiographic window.

No patient received drugs that prolong the QT interval during the 6-month follow-up period.

All patients had blood samples and clinical, echocardiographic, and electrocardiographic examinations at screening (M0) and after 6 months of treatment (M1).

From the blood samples, high sensitivity cardiac troponin I (hs-cTnl), N-terminal pro-brain natriuretic peptide (NTproBNP), and testosterone were analyzed.

2.1 | Echocardiographic assessment

Complete echocardiographic examinations were performed using a Philips IE33 system, following the guidelines for image acquisitions. LVEF was measured by the biplane method of disks. By tissue Doppler imaging, using the apical four-chamber view, septal and lateral early diastolic (e'), and late diastolic (a') mitral annular velocities were measured, then averaged, and E/e' ratio was calculated. Speckle-tracking imaging with the Philips Q-Lab software was used for the assessment of global longitudinal left ventricular systolic strain (GLS) and global circumferential left ventricular systolic strain (GCS), after manually optimizing the adequacy
of tracking. An acquisition was considered uninterpretable if the endocardial border was not clearly defined and the recordings needed to be rejected in more than two myocardial segments. This was an eligibility criterion, thus was checked before M0, and only patients with interpretable speckle-tracking acquisitions were included in the study.

According to current guidelines, in adults, GLS < 16% is considered abnormal, GLS > 18% normal, and GLS 16% to 18% is borderline, and a fall of GLS by more than 15% from the baseline value under chemotherapy suggests cardiotoxicity. These cutoff values were used in our study.

Mechanical dispersion was assessed using the standard deviation of time intervals from the start of Q/R on ECG to peak myocardial longitudinal strain in the 17-segment left ventricular model (MDSD) and the difference between the longest and shortest time-to-peak strain intervals (MDdelta) (Figure 1). Both MDSD and MDdelta values were corrected for heart rate using the Fridericia formula.

All measurements were performed by a single experienced member of the team, blinded to the patients’ data.

### 2.2 Electrocardiographic assessment

The following ECG parameters were measured: QT interval, between the onset of the QRS complex and the end of the T-wave measured in all leads; Tpeak-Tend wave interval (Tpe) between T-wave peak and T-wave end in the precordial leads; Tpe/QT ratio; Tpe dispersion (Tped) as the difference between the highest and lowest value of Tpe intervals. The end of the T-wave was measured by the method of the tangent to the steepest slope of the descending portion of the T-wave (Figure 1). The maximum Tpe value (maxTpe) and mean Tpe value (meanTpe) were taken into account during the data analysis. QT, Tpe, and Tped were corrected for heart rate using the Fridericia formula (QTc = QT/RRI1/3). Leads were considered uninterpretable if the T-wave amplitude was lower than 0.1 mV or if biphasic T-waves were present. The measurements were performed on a stable RR interval, with a heart rate between 50 and 90 beats/min.

For each patient, we compared the variations in the laboratory, echocardiographic, and ECG parameters between visits.

### 2.3 Statistical analysis

Data are presented as means ± standard deviation for numerical variables and as absolute numbers and percentages for categorical variables. Normality was checked using the Shapiro–Wilk test. For numerical variables, parametric (two-tailed Student’s t test for dependent samples or groups), or nonparametric (Mann-Whitney) tests were used, according to the distribution of data. Linear regression and Pearson’s correlation coefficient or Spearman’s correlation coefficient were used to assess the correlation between different numerical variables, according to their distribution. For comparison of categorical data proportions, chi-squared and Fischer’s exact tests were used. The statistical analysis and the graphic representations of data were performed using STATISTICA version 8. A p-value < 0.05 was considered statistically significant.

### 3 RESULTS

A total of 31 patients, 69.7 ± 7.3 years old, were included. The basic demographic characteristics and baseline cardiovascular therapy of the study group are shown in Table 1. The baseline serum testosterone level at M0 was 2.2 ± 0.2 ng/mL. It decreased significantly to 0.1 ± 0.13 ng/mL after 6 months of treatment (P < .001) (normal values in men: 1.75-7.81 ng/mL). Echocardiographic and ECG data are depicted in Table 2.

At M0, the mean GLS was −16.93 ± 3.89%, and 11 (35.4%) patients had abnormal baseline GLS values. Between M0 and M1, there was a reduction in GLS to a mean value of −14.43 ± 3.57% (P < .001). The GLS impairment between visits (defined as percentage fall from baseline) was similar in patients with or without abnormal baseline GLS (11.4% ± 23.6% versus 13.8 ± 17.1%, P = .74). Eighteen (56%) patients had a more than 15% GLS fall from M0 to M1, irrespective of the baseline GLS value. GCS did not vary significantly between visits (Table 2). Between M0 and M1, there were also statistically significant prolongations of MDSD, MDdelta on echocardiography, and of QTc, max Tpe/QT, maxTpe, meanTpe, Tped on ECG (Table 2).

The laboratory study demonstrated a statistically significant elevation of hs-cTnI between M0 and M1 and no significant variation of NTproBNP (Table 2). GLS variation correlated with max Tpe variation (Figure 2) and did not correlate with other ECG or echocardiographic parameters, including LVEF, MDSD, and MDdelta, and neither with hs-cTnI or NTproBNP variations (Table 3). However, patients with abnormal baseline GLS values had a significantly greater increase in hs-cTnI level compared with those with normal baseline GLS values (mean variation of hs-cTnI between visits 1.8 ± 1.8 ng/mL versus 0.2 ± 1.2 ng/mL, respectively, P = .02).

MDdelta variation presented a moderate correlation with hs-cTnI variation (Table 3, Figure 3).

The history of chronic coronary syndromes, present in 18 (58.1%) of the study group, did not influence the changes recorded in the echocardiographic, ECG, and myocardial injury parameters under ADT during the observation period (Table 4). Because of the lack of representativity, the other comorbidities did not allow us to analyze their possible contribution to the extent of cardiac changes under ADT.

Patients remained in a stable cardiac condition during the first 6 months of ADT, and no severe ventricular arrhythmias or signs and symptoms of new-onset or worsening heart failure were recorded during this follow-up period.
FIGURE 1  Example of measurement of the longitudinal strain derived mechanical dispersion (top) and electrocardiographic parameters of repolarization (bottom); RV, right ventricle; LA, left atrium; LV, left ventricle; GLS, global longitudinal strain; MD, mechanical dispersion
TABLE 1  Baseline characteristics of the study group

| Total (n = 31) |
|----------------|
| Age (years)    | 69.7 ± 7.3 |
| Cardiovascular risk factors and comorbidities |          |
| Body mass index > 27 kg/m² | 8 (25.8%) |
| Diabetes mellitus | 7 (22.5%) |
| Grade 3 chronic kidney disease | 5 (16.1%) |
| Hypertension | 22 (70.9%) |
| Stable coronary artery disease | 18 (58.0%) |
| Old myocardial infarction | 5 (16.1%) |
| Heart failure NYHA class II | 3 (9.7%) |
| Left ventricular ejection fraction (%) | 60.7 ± 4.9 |
| Cardiovascular drugs |          |
| Betablockers | 16 (51.6%) |
| Angiotensin-converting enzyme inhibitors | 19 (61.3%) |
| Aspirin | 14 (45.1%) |
| Statins | 11 (35.4%) |
| Calcium channels blockers | 7 (22.5%) |

Abbreviation: NYHA, New York Heart Association classification of heart failure.

4  | DISCUSSION

ADT is the cornerstone of the treatment in patients with advanced prostate cancer, and there are concerns about the cardiovascular safety of these drugs. Some reported data show that the use of ADT is associated with a higher risk of coronary artery disease, sudden cardiac death, and myocardial infarction, compared with orchietomy alone.3,6 Tsai HK et al5 studied 3262 patients with prostate cancer from the Cancer of the Prostate Strategic Urologic Research Endeavor database. 1015 patients received ADT for 1.0-32.9 months, associated with prostatectomy. The 5-year cumulative incidence of cardiovascular death was 5.5% (95% CI = 1.2% to 9.8%) in patients older than 65 years receiving ADT and 2% (95% CI = 1.1% to 3.0%) in those treated with prostatectomy only. However, according to other scientific data, a low serum testosterone level by itself is associated with QTc interval prolongation on ECG, accelerated ischemic heart disease, higher risk of myocardial infarction, and cardiovascular death.5 We observed in our patients a statistically significant reduction in GLS from -16.93 ± 3.89% at M0 to -14.43 ± 3.57% at M1 (P < .001) after 6 months of treatment with ADT. Moreover, 18 (56%) patients had a more than 15% GLS reduction from baseline, which is considered a sign of cardiotoxicity in patients under chemotherapy.9 Our results are in agreement with other data in the literature. Kanar BG et al22 studied 49 patients 71.5 ± 6.7 years old with prostate cancer, treated with radiotherapy and ADT versus 32 patients, 71.9 ± 7 years old treated with prostatectomy alone and described the reduction in GLS, GCS, and radial strain after 6 months of treatment only in patients who received ADT. Post HK et al23 demonstrated in 3 patients 66 ± 7 years old with prostate cancer receiving ADT that GLS decreased from the resting value during exercise, compared to 4 age-matched healthy subjects in whom GLS increased during exercise. In addition, in our patients, neither the baseline GLS value nor the chronic coronary syndrome associated with a greater extent of GLS alteration.

To the best of our knowledge, this study is the first attempt to assess speckle-tracking-derived mechanical dispersion in patients on ADT. In our patients, we observed a statistically significant prolongation of mechanical dispersion that moderately correlated with the significant elevation of hs-cTnI after 6 months of ADT. Studies are pointing to an association between left ventricular systolic impairment revealed by an altered GLS and a rise in myocardial injury markers expressed by hs-cTn elevation in patients who develop heart failure under anthracycline therapy.24 In our study, mechanical dispersion prolongation, and not GLS reduction correlated with hs-cTnI elevation after 6 months of ADT. This fact might suggest that cardiac changes under ADT could be more subtle than under chemotherapy. Temporal inhomogeneity of the ventricular deformation assessed by mechanical dispersion parameters could be more sensitive than the amplitude of the systolic strain assessed by GLS in detecting such subtle cardiac changes under ADT. However, hs-cTnI elevation between M0 and M1 was more pronounced in patients with an abnormal GLS at admission demonstrating that a previous subclinical cardiac dysfunction may be associated with a higher probability of developing cardiac toxicity. This finding is consistent with other studies that showed that patients with previous cardiovascular diseases had a higher risk of cardiac side effects on ADT.25 We observed a statistically significant prolongation of QTc interval, maxTpe/QT ratio, maxTpe, and mean Tpe on ECG after 6 months of treatment. These findings are in line with the results of other studies demonstrating the prolongation of QTc interval on ECG related to arrhythmic effects in patients on ADT with hypogonadism.3,8 We found a correlation between the prolongation of max Tpe and the alteration of GLS, suggesting a deleterious effect on both mechanical and electrical cardiac activity.

LVEF did not significantly vary between M0 and M1. These data are in line with the knowledge that LVEF is not sensitive to subtle cardiac changes.20 At the same time, NTproBNP did not significantly vary after 6 months of ADT. In contrast, there are studies reporting elevation of NTproBNP under chemotherapy, related to asymptomatic cardiac events.26-28 In clinical practice, it is difficult to separate the deleterious effects of ADT from those of hypogonadism itself on cardiac cell repolarization. Both of them can modify the myocardial transmembrane repolarization K currents and may induce torsade de points and sudden cardiac death.3,29,30 However, some clinical trials and registry data suggest that the risk is greater in patients who receive ADT.3,5,6,29 In our study, as there was no group treated with orchietomy alone, we could not differentiate between a potential cardiotoxic drug effect and effects of hypogonadism itself on the assessed parameters.

In summary, during the first 6 months, ADT and subsequent hypogonadism induced statistically significant changes in some of the
### TABLE 2

Variations in the measured parameters between visits in the study group

| Parameter                                | M0              | M1              | P    |
|------------------------------------------|-----------------|-----------------|------|
| **Echocardiographic parameters**         |                 |                 |      |
| SBP during assessment (mm Hg)            | 141 ± 18        | 138 ± 15        | .24  |
| DBP during assessment (mm Hg)            | 83 ± 9          | 80 ± 9          | .10  |
| HR during assessment (beats/minute)      | 72 ± 13         | 71 ± 11         | .54  |
| E/A ratio                                | 0.89 ± 0.35     | 0.89 ± 0.28     | .96  |
| E/e' ratio                               | 9.14 ± 2.61     | 9.82 ± 2.32     | .09  |
| DTE (ms)                                 | 243.80 ± 60.04  | 229.67 ± 53.06  | .15  |
| IVRT (ms)                                | 111.03 ± 24.20  | 111.74 ± 22.28  | .82  |
| GLS (%)                                  | -16.93 ± 3.89   | -14.43 ± 3.57   | <.001|
| GCS (%)                                  | -17.70 ± 5.38   | -16.71 ± 4.81   | .27  |
| LVEF (%)                                 | 60.69 ± 4.96    | 59.83 ± 5.62    | .33  |
| MDS (ms)                                 | 77.39 ± 21.43   | 89.09 ± 26.99   | .004 |
| MDS_{delta} (ms)                         | 225.32 ± 78.29  | 259.92 ± 108.37 | .02  |
| **Electrocardiographic parameters**      |                 |                 |      |
| QRS (ms)                                 | 118.0 ± 24.6    | 114.4 ± 16.6    | .50  |
| QTc (ms)                                 | 458.8 ± 43.3    | 476.9 ± 39.7    | .03  |
| mean Tpe (ms)                            | 83.3 ± 16.8     | 90.7 ± 19.3     | .02  |
| max Tpe (ms)                             | 105.4 ± 23.2    | 119.5 ± 26.4    | .01  |
| Tped (ms)                                | 39.67 ± 18.43   | 49.98 ± 19.92   | .03  |
| mean Tpe/QT ratio                        | 0.199 ± 0.04    | 0.206 ± 0.04    | .36  |
| max Tpe/QT ratio                         | 0.246 ± 0.04    | 0.268 ± 0.05    | .01  |
| **Myocardial injury markers**            |                 |                 |      |
| hs-cTnI (ng/L)                           | 4.64 ± 5.37     | 5.40 ± 6.35     | .01  |
| NTproBNP (pg/mL)                         | 366.69 ± 576.86 | 343.66 ± 326.38| .74  |

Abbreviations: DBP, diastolic blood pressure; DTE, early mitral flow deceleration time; GCS, global circumferential strain; GLS, global longitudinal strain; HR, heart rate; hs-cTnI, high sensitivity cardiac troponin I; IVRT, isovolumic relaxation time; LVEF, left ventricular ejection fraction; NTproBNP, N- terminal pro-brain natriuretic peptide; QTc, Fridericia corrected QT interval; SBP, systolic blood pressure; Tpe, Tpeak-end interval; Tped, Tpeak-end interval dispersion.

**FIGURE 2** Scatterplot of GLS variation against maxTpe variation; GLS, global longitudinal strain; maxTpe, maximum T peak-Tend interval

**FIGURE 3** Scatterplot of MDS_{delta} variation against hs-cTnI variation; MD, mechanical dispersion; hs-cTnI, high sensitivity cardiac troponin I
echocardiographic parameters, ECG parameters, and myocardial injury markers as follows: impairment of GLS on echocardiography, which correlated with the prolongation of maxTpe interval on ECG; prolongation of the mechanical dispersion correlated with elevation of hs-cTnI; prolongation of QTc interval, mean Tpe interval, and max Tped/QT ratio; and no variation of NTproBNP and LVEF. Patients with a baseline abnormal GLS value had a greater increase in hs-cTnI level, suggesting that baseline subclinical cardiac dysfunction might be associated with a higher probability of cardiotoxicity. By understanding these effects, we will be able to improve the monitoring strategy.

**TABLE 3** Correlation coefficients ($r$) and statistical significance of correlations between variations of the parameters measured

| Parameter | LVEF | GLS | GCS | MDSD | MDdelta |
|-----------|------|-----|-----|------|---------|
|           | Corr. coef.$^a$ | P    | Corr. coef.$^a$ | P    | Corr. coef.$^a$ | P    |
| Myocardial injury markers | | | | | | |
| hs-cTnI | $-0.13$ | $.47$ | $0.04$ | $.83$ | $-0.01$ | $.96$ | $0.30$ | $.10$ | $0.40$ | $.02$ |
| NTproBNP | $-0.12$ | $.52$ | $-0.13$ | $.50$ | $-0.14$ | $.47$ | $-0.28$ | $.13$ | $-0.16$ | $.39$ |
| Electrocardiographic indices of repolarization | | | | | | |
| QTc | $-0.21$ | $.25$ | $0.16$ | $.38$ | $0.23$ | $.23$ | $0.02$ | $.93$ | $-0.06$ | $.74$ |
| Mean Tpe | $0.17$ | $.35$ | $0.29$ | $.11$ | $0.11$ | $.57$ | $0.05$ | $.80$ | $-0.20$ | $.28$ |
| Max Tpe | $0.12$ | $.51$ | $0.40$ | $.02$ | $0.31$ | $.10$ | $0.10$ | $.95$ | $-0.04$ | $.81$ |
| Tped | $0.07$ | $.69$ | $-0.24$ | $.19$ | $0.01$ | $.94$ | $0.31$ | $.08$ | $0.10$ | $.58$ |
| Mean Tpe/QT | $0.28$ | $.12$ | $0.07$ | $.71$ | $-0.07$ | $.72$ | $0.05$ | $.77$ | $-0.19$ | $.31$ |
| Max Tpe/QT | $0.16$ | $.40$ | $0.23$ | $.21$ | $0.34$ | $.06$ | $-0.07$ | $.69$ | $-0.16$ | $.38$ |

**Abbreviations:** GCS, global circumferential strain; GLS, global longitudinal strain; hs-cTnI, high sensitivity cardiac troponin I; LVEF, left ventricular ejection fraction; NTproBNP, N-terminal pro-brain natriuretic peptide; QTc, Fridericia corrected QT interval; Tpe, Tpeak-end interval; Tped, Tpeak-end interval dispersion.

$^a$Pearson’s $r$ for normally distributed variables and Spearman’s rho for nonnormally distributed variables; variations in LVEF, MD delta, hs-cTnI, and NTproBNP had a nonnormal distribution.

**TABLE 4** The extent of the measured parameters’ variations in patients with and without chronic coronary syndromes

| Parameter | With chronic coronary syndromes | Without chronic coronary syndromes | P |
|-----------|---------------------------------|-----------------------------------|---|
| Echocardiographic parameters | | | |
| GLS (%) | $2.35 \pm 3.25$ | $2.7 \pm 3.48$ | $.77$ |
| GCS (%) | $0.73 \pm 3.41$ | $1.30 \pm 6.42$ | $.75$ |
| LVEF (%) | $-1.85 \pm 5.48$ | $0.50 \pm 3.89$ | $.19$ |
| MDSD (ms) | $8.12 \pm 16.93$ | $16.65 \pm 26.10$ | $.27$ |
| MDdelta (ms) | $15.50 \pm 65.28$ | $61.04 \pm 92.94$ | $.12$ |
| Electrocardiographic parameters | | | |
| QTc (ms) | $16.26 \pm 38.62$ | $20.60 \pm 51.70$ | $.79$ |
| mean Tpe (ms) | $6.29 \pm 16.10$ | $8.87 \pm 18.95$ | $.68$ |
| max Tpe (ms) | $11.42 \pm 30.72$ | $17.56 \pm 28.90$ | $.57$ |
| Tped (ms) | $5.78 \pm 26.95$ | $16.56 \pm 23.16$ | $.25$ |
| mean Tpe/QT ratio | $0.006 \pm 0.034$ | $0.007 \pm 0.051$ | $.95$ |
| max Tpe/QT ratio | $0.020 \pm 0.044$ | $0.024 \pm 0.053$ | $.85$ |
| Myocardial injury markers | | | |
| hs-cTnI (ng/L) | $0.49 \pm 1.63$ | $1.10 \pm 1.55$ | $.30$ |
| NTproBNP (pg/mL) | $-71.17 \pm 515.77$ | $43.63 \pm 72.11$ | $.43$ |

**Abbreviations:** GCS, global circumferential strain; GLS, global longitudinal strain; hs-cTnI, high sensitivity cardiac troponin I; LVEF, left ventricular ejection fraction; NTproBNP, N-terminal pro-brain natriuretic peptide; QTc, Fridericia corrected QT interval; Tpe, Tpeak-end interval; Tped, Tpeak-end interval dispersion.
of the patients, to prevent arrhythmic events and left ventricular function impairment.

Our patients’ clinical cardiological status under ADT remained stable during the 6-month follow-up period, consistent with other reports that did not register any clinical change in the first months of treatment. This study has limitations arising from the research design and also the methodology used. This was a single-center research, with relatively restrictive inclusion and exclusion criteria meant to minimize potential confounder factors’ effects on the ECG and echocardiographic parameters assessed; thus, a small number of patients analyzed and a relatively short duration of follow-up. The antiandrogen treatment inhomogeneity in the study group, with various agents from different ADT classes and also combined medical therapies, did not allow us to compare the effects of the different ADT agents. Further research is needed on larger cohorts and with longer follow-up periods to assess the long-term arrhythmic and heart failure risk and to design a diagnosis and management strategy for potential cardiovascular deleterious effects of hypogonadism and ADT in patients with prostate cancer. Regarding the methodology, potential limitations for widespread use of the strain-derived parameters in clinical practice arise from the influence of acoustic window quality on proper endocardial border delineation, the possibility of important intra- and inter-observer variability. Additionally, there are significant differences between vendors regarding the range of normal values for GLS assessed by speckle-tracking echocardiography, we might expect the same for mechanical dispersion.

In conclusion, ADT and the subsequent hypogonadism induce subtle cardiac changes in the first 6 months of treatment, expressed by the alteration of GLS, electrocardiographic repolarization parameters, and elevation of hs-cTnI. The hs-cTnI increase is more pronounced in patients with an abnormal baseline GLS value. The assessment of mechanical dispersion in addition to the traditional parameters of arrhythmic risk might have additive value for cardiotoxicity evaluation.

CONFLICT OF INTEREST
None.

AUTHORS’ CONTRIBUTION
ACDG, VJ, ITN, and GSG participated in the study conception and design. ACDG, AC, ASH, and GSG organized the database. ACDG, ASH, GDR, ASCR, ITN, and GSG contributed to data acquisition and interpretation. AC performed the statistical analysis. ACDG, AC, ASH, and GDR drafted the manuscript. VJ, ITN, ASCR, and GSG performed a critical revision for important intellectual content.

DATA AVAILABILITY STATEMENT
Data are available on request from the authors.

REFERENCES
1. Salem J-E, Waintraub X, Courtillot C, et al Hypogonadism as a reversible cause of torsades de pointes in men. Circulation. 2018; 138(1):110-113.
2. Salem J-E, Alexandre J, Bachelot A, et al Influence of steroid hormones on ventricular repolarization. Pharmacol Ther. 2016; 167:38-47.
3. Lester JF, Mason MD. Cardiovascular effects of hormone therapy for prostate cancer. Drug Healthc Patient Saf. 2015; 7:129-138.
4. Basaria S. Cardiovascular disease associated with androgen-deprivation therapy: time to give it due respect. J Clin Oncol. 2015; 33(11):1232-1234.
5. Tsai HK, D’Amico AV, Sadetsky N, et al Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99(20):1516-1524.
6. Punnen S, Cooperberg MR, Sadetsky N, et al Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011; 29(26):3510-3516.
7. Basch E, Loblaw DA, Oliver TK, et al Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014; 32(30):3436-3448.
8. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24(27):4448-4456.
9. Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian J Androl. 2012; 14:428-435.
10. Zamorano JL, Lancellotti P, Rodrigo Muñoz D, et al 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016; 37:2768-2801.
11. Laufer-Perl M, Arnold JH, Mor L, et al The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy. Clin Res Cardiol. 2020; 109(2):255-262.
12. Pellerin D, Sharma R, Elliott P, et al Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function. Heart. 2003; 89:i102-i115.
13. Haugaa KH, Smedsrud MK, Steen T, et al Mechanical dispersion assessed by myocardial strain in patients after myocardial infarction for risk prediction of ventricular arrhythmia. JACC Cardiovasc Imaging. 2010; 3(3):247-256.
14. Tse G, Yan BP. Traditional and novel electrocardiographic conduction and repolarization markers of sudden cardiac death. Europace. 2017; 19:712-721.
15. Candan O, Gecmen C, Bayam E, et al Mechanical dispersion and global longitudinal strain by speckle-tracking echocardiography: predictors of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy. Echocardiography. 2017; 34(6):835-842.
16. Galdersen M, Henein MY, D’hooge J, et al Recommendations of the European association of echocardiography how to use echodoppler in clinical trials: different modalities for different purposes. Eur J Echocardiogr. 2011; 12(5):339-353.
17. Negishi K, Negishi T, Hare JL, et al Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013; 26(5):493-498.
18. Yang H, Wright L, Neghishi T, et al Research to practice: assessment of left ventricular global longitudinal strain for surveillance of cancer chemotherapeutic-related cardiac dysfunction. JACC: Cardiovasc Imaging. 2018; 11(8):1196-1201.

ORCID
Ana Ciobanu https://orcid.org/0000-0001-9718-0121
19. Ciobanu A, Tse G, Liu T, et al Electrocardiographic measures of repolarization dispersion and their relationships with echocardiographic indices of ventricular remodeling and premature ventricular beats in hypertension. J Geriatr Cardiol. 2017;14(12):717-724.

20. Mor-Avi V, Lang RM, Badano LP, et al Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications: endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24:277-313.

21. Vandenberk B, Vandael E, Robyns T, et al Which QT correction formulae to use for QT monitoring? J Am Heart Assoc. 2016;5(6).

22. Kanar BG, Ozben B, Sunbul M, et al Androgen-deprivation therapy impairs left ventricle functions in prostate cancer patients. Int Urol Nephrol. 2019;51(7):1107-1112.

23. Post HK, Lovoy GM, Banister HR, et al Left ventricular strain and strain rate responses to submaximal exercise in prostate cancer patients treated with androgen deprivation therapy. FASEB J. 2018;32, No. 1, supplement.

24. Raderer M, Kornek G, Weinlander G, et al Serum troponin T levels in adults undergoing anthracycline therapy. J Natl Cancer Inst. 1997;89:171.

25. Levine GN, D’Amico AV, Berger P, et al Androgen deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833-840.

26. Sandri MT, Salvatici M, Cardinale D, et al N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51(8):1405-1410.

27. Wang Y, Bao L, Chu B, et al Progressive elevation of NT-ProBNP during chemotherapy is related to asymptomatic cardiovascular events in patients with multiple myeloma. Clin Lymphoma, Myeloma Leuk. 2019;19(3):167-176.e1.

28. Efthathiou JA, Bae K, Shipley WU, et al Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92–02. Eur Urol. 2008;54(4):816-823.

29. Bhatia N, Santos M, Jones LW, et al Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE Steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133(5):537-541.

30. Salem J-E, Yang T, Moslehi JJ, et al Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to ipsc-cardiomyocytes. Circulation. 2019;140(13):1070-1080.

How to cite this article: Gheorghe ACD, Ciobanu A, Hodorogea AS, et al. Subclinical left ventricular dysfunction in men under androgen deprivation therapy for prostate cancer, revealed by speckle-tracking-derived parameters, repolarization, and myocardial injury markers. Echocardiography. 2021;38:632–640. https://doi.org/10.1111/echo.15043